139 White Matter Connectivity in Narcolepsy Type 1 Results Demographic and clinical data Data from age-and-sex-matched patients and controls were included in a 12:11 ratio. As shown in Table 1, there were no significant demographic and clinical differences between the groups, except for ESS score, which was higher in patients [10.08 ± 3.00 vs. 2.64 ± 1.96; t(21) = −6.97, p < .001]. The patient with a 138 pg/mL hypocretin-1 level was no outlier in any of the demographic or DTI analyses. Table 1: Population characteristics Patients (n = 12) Controls (n = 11) P-value Male:female (N:N) 8:4 7:4 0.879 Age (years) Mean (SD) 33.25 (10.50) 31.82 (13.39) 0.777 Median (IQR) 32 (24.25-40.5) 26 (23-38.5) Range 21-52 18-55 IQ score (mean, SD) 110.58 (10.73) 111.30 (8.25) 0.865 Age of onset EDS (years, mean, SD) 19.42 (9.15) - EDS duration (years, median, IQR) 10.00 (6.0025.25) - Cataplexy presence 9/12 - Cataplexy and/or hypocretin deficient* 12/12 - HLA DQB1*0602 presence 12/12 - ESS score (mean, SD) 10.08 (3.00) 2.64 (1.96) 0.001 MSLT Sleep latency (minutes, mean, SD) 4.62 (3.64) - SOREM periods (mean, SD) 2.58 (1.57) - Polysomnography TST (minutes, mean, SD) 426.50 (25.33) - Sleep efficiency (% of TST, mean, SD) 91.89 (5.49) - Stage 1 sleep (% of TST, mean, SD) 12.75 (7.19) - Stage 2 sleep (% of TST, mean, SD) 43.91 (10.38) - Stage 3-4 sleep (% of TST, mean, SD) 17.40 (8.65) - Stage REM sleep (% of TST, mean, SD) 23.86 (6.00) - 5
RkJQdWJsaXNoZXIy MjY0ODMw